Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ALK mut TP53 wild-type||neuroblastoma||sensitive||Crizotinib + Cyclophosphamide + Topotecan||Preclinical - Pdx & cell culture||Actionable||In a preclinical study, Xalkori (crizotinib) demonstrated synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) in patient-derived neuroblastoma cell lines harboring Alk mutations and functional TP53, resulting in growth inhibition in culture and tumor regression in animal models (PMID: 26438783).||26438783|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|